MedPath

ratiopharm GmbH

ratiopharm GmbH logo
🇩🇪Germany
Ownership
Subsidiary
Established
1973-01-01
Employees
1K
Market Cap
-
Website
http://www.ratiopharm.de

Clinical Trials

5

Active:2
Completed:3

Trial Phases

1 Phases

Phase 1:2

Drug Approvals

8

EMA:8

Drug Approvals

Pazenir

Authorization Status
Authorised
Approval Date
May 6, 2019
EMA

Memantine ratiopharm

Authorization Status
Authorised
Approval Date
Jun 12, 2013
EMA

Desloratadine ratiopharm

Authorization Status
Authorised
Approval Date
Jan 13, 2012
EMA

Levetiracetam ratiopharm

Authorization Status
Authorised
Approval Date
Aug 26, 2011
EMA

Leflunomide ratiopharm

Authorization Status
Authorised
Approval Date
Nov 28, 2010
EMA

Sildenafil ratiopharm

Authorization Status
Authorised
Approval Date
Dec 23, 2009
EMA

Eporatio

Authorization Status
Authorised
Approval Date
Oct 29, 2009
EMA

Ratiograstim

Authorization Status
Authorised
Approval Date
Sep 15, 2008
EMA

Clinical Trials

Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials

Phase 1
2 (100.0%)

Cafedrin/Theodrenalin (Akrinor®) Versus Ephedrine for Treatment of Hypotension in the Peri-operative Phase in Inpatient Setting

Completed
Conditions
Hypotension
Interventions
First Posted Date
2016-09-08
Last Posted Date
2021-11-09
Lead Sponsor
Ratiopharm GmbH
Target Recruit Count
2013
Registration Number
NCT02893241
Locations
🇩🇪

Teva Investigational Site 133, Aachen, Germany

🇩🇪

Teva Investigational Site 122, Amberg, Germany

🇩🇪

Teva Investigational Site 106, Aue, Germany

and more 71 locations

Multiple Dose BE Study With Nevirapine 400mg PR Tablets

Phase 1
Completed
Conditions
HIV-1
Interventions
First Posted Date
2014-07-28
Last Posted Date
2015-08-25
Lead Sponsor
Ratiopharm GmbH
Target Recruit Count
46
Registration Number
NCT02202005
Locations
🇬🇧

Chelsea and Westminster NHS Foundation Trust, London, United Kingdom

News

No news found
© Copyright 2025. All Rights Reserved by MedPath